GG Group Ventures’s Jade Biosciences JBIO Stock Holding History

GG Group Ventures’s Portfolio JBIO Stock Details JBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-374	Closed	-$22.9K	–	52
2024 Q2	$22.9K	Buy	+374	New	+$248K	0.03%	50

Other funds holding JBIO

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

GG Group Ventures's JBIO Position: Q3 2024 in Review

GG Group Ventures sold out of Jade Biosciences (JBIO) in Q3 2024, closing a stake of 374 shares — an estimated $22.9K sold.

GG Group Ventures first reported a position in JBIO in Q2 2024 and held it in 1 quarter. The position peaked at $22.9K in Q2 2024. 72 funds tracked by Wall St. Rank hold JBIO as of Q3 2024.

GG Group Ventures reported no remaining Jade Biosciences position as of Q3 2024 after selling out during the quarter.
GG Group Ventures sold 374 Jade Biosciences shares in Q3 2024, an estimated $22.9K.
GG Group Ventures first reported a position in Jade Biosciences in Q2 2024 and held it in 1 quarter.
GG Group Ventures's Jade Biosciences position peaked at $22.9K in Q2 2024.
72 funds tracked by Wall St. Rank held Jade Biosciences as of Q3 2024.

Based on GG Group Ventures's 13F filing for Q3 2024, filed 18 Nov 2024.